RRB NTPC · प्रश्न 34
2025 मध्ये सुरू झालेली, कोणती स्वदेशी CAR T-सेल थेरपी भारताच्या कर्करोगावरील उपचार आणि जैवतंत्रज्ञान परिसंस्थेतील एक ऐतिहासिक टप्पा ठरली?
उत्तर दाखवा आणि स्पष्टीकरणस्पष्टीकरण पहा
उत्तर: (B) नेक्सकार19 स्वदेशी CAR T-सेल थेरपी
• NexCAR19 is India's landmark indigenous CAR T-cell cancer therapy. • CAR (Chimeric Antigen Receptor) T-cell therapy genetically engineers a patient's T-cells to target cancer cells. Related Facts: • NexCAR19 (Actalycabtagene autoleucel) is India's first indigenous CAR T-cell therapy, developed jointly by IIT Bombay, Tata Memorial Centre, and ImmunoACT. • It targets the CD19 protein in patients with relapsed or refractory B-cell lymphomas and acute lymphoblastic leukemia. • NexCAR19 reduced treatment costs to around ₹30–40 lakh compared to ₹3–4 crore for imported CAR T-cell therapies. Correct Answer: (b) NexCAR19 indigenous CAR T-cell therapy
